RELATED CONTENT
May 14, 2012 — Lantheus Medical Imaging Inc. announced new manufacturing and supply agreements with Jubilant HollisterStier LLC (JHS). Under separate agreements, JHS will manufacture Cardiolite (kit for the preparation of technetium Tc99m sestamibi for injection) products and Neurolite (kit for the preparation of technetium Tc99m bicisate for injection), each for an initial term of five years and each with an option to renew for an additional five years thereafter.
May 14, 2012 
November 14, 2011 – The American Society of Echocardiography (ASE) reported that the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) has recognized the value of contrast agents in echocardiography and made very positive revisions to the U.S. label for Definity, an ultrasound contrast agent produced by Lantheus Medical Imaging.
November 14, 2011 
November 3, 2011 – Lantheus Medical Imaging announced important changes to the U.S. product label for Definity Vial for (perflutren lipid microsphere) Injectable Suspension. The contrast agent is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.
November 03, 2011 October 31, 2011 –Lantheus Medical announced it has been awarded a three-year supplier contract with Premier Purchasing Partners, the group purchasing unit of the Premier healthcare alliance, for its radiopharmaceutical imaging agents.
October 31, 2011 
October 26, 2011 –Lantheus Medical Imaging announced it has been awarded three-year supplier contracts with Premier Purchasing Partners, the group purchasing unit of the Premier healthcare alliance, in the category of cardiac ultrasound contrast media for its ultrasound contrast agent, Definity Vial for (perflutren lipid microsphere) Injectable Suspension, and its magnetic resonance angiography (MRA) blood pool imaging agent, Ablavar (gadofosveset trisodium).
October 26, 2011 
May 18, 2011, – Lantheus Medical Imaging Inc. announced data from a Phase 2 clinical trial that demonstrated positron emission tomography (PET) myocardial perfusion imaging with flurpiridaz F 18 provided superior image quality, diagnostic certainty and diagnostic performance for detecting coronary artery disease (CAD) compared to single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI), the current standard for the non-invasive detection of CAD. The data also demonstrated a positive safety profile for PET imaging with flurpiridaz F 18.
May 18, 2011 
March 11, 2011 – U.S. Food and Drug Administration (FDA) and Lantheus Medical Imaging Inc. today reached agreement on a phase 3 clinical trial design to assess myocardial perfusion using flurpiridaz F18 positron emission tomography (PET) imaging in patients with suspected or known coronary artery disease (CAD).
March 11, 2011 
December 17, 2010 – An ultrasound contrast agent is under review by the U.S. Food and Drug Administration (FDA) for use in stress echocardiography. Lantheus Medical Imaging recently submitted a supplemental new drug application for its Definity (Perflutren Lipid Microsphere) Injectable Suspension.
December 17, 2010 December 10, 2010 – The first commercial production of generators using molybdenum-99 (Mo-99) produced with low-enriched uranium (LEU) targets in the United States is underway. The Lantheus TechneLite (Technetium Tc99m) generator received the first commercial scale batch from NTP Radioisotopes, a subsidiary of the Nuclear Energy Corporate of South Africa (NESCA)
December 10, 2010 
October 14, 2010 – An injectable magnetic resonance angiography (MRA) blood pool imaging agent has been released in Canada. Ablavar, which is made by Lantheus Medical Imaging and previously marketed as Vasovist, is indicated for contrast-enhanced MRA for visualization of abdominal or limb vessels in patients with suspected or known vascular disease.
October 14, 2010